Acción HEMISPHERX BIOPHARMA, INC
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Hemispherx BioPharma, Inc Nyse

Acciones

US42366C1036

Precio de cierre Nyse
Otros sitios de cotización
- USD - Gráfico intradía de Hemispherx BioPharma, Inc
05/06 Transcript : AIM ImmunoTech Inc. - Special Call
16/05 Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Recent Stockholder Lawsuits In Delaware Challenge Common Advance Notice Bylaw Provisions
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Challenges To Advance Notice Bylaws Are Spiking
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
North American Morning Briefing : Stocks Seen -2-
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción AIM
  4. Acción
  5. Noticias Hemispherx BioPharma, Inc
  6. Otros idiomas